Combination therapy for chronic obstructive pulmonary disease: Clinical aspects

Proceedings of the American Thoracic Society

Volumn 2, Issue 4, 2005, Pages 272-281

  Donohue, James F ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

agonist; Anticholinergic; Inhaled corticosteroid; Theophylline

Indexed keywords

ACETYLCYSTEINE; ANTIINFLAMMATORY AGENT; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLYCOPYRRONIUM BROMIDE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; ORCIPRENALINE; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

BRONCHODILATATION; BRONCHOSPASM; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; FRACTURE; HUMAN; LUNG FUNCTION; NAUSEA; PRACTICE GUIDELINE; QUALITY OF LIFE; VERTEBRA FRACTURE;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; AEROSOLS; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 27644516884     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200505-047SR     Document Type: Conference Paper

References (99)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease-updated 2003. Bethesda: National Institutes of Health, National Heart, Lung, and Blood Institute; 2003. Available from: www.goldcopd.com/revised.pdf (accessed March 8, 2005).
2. Celli BR, MacNee W. ATS/ERS Task Force: standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946.
3. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312.
4. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994;105:1411-1419.
5. Ikeda A, Nishimura K, Koyama H, Izumi T. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: comparison with ipratropium bromide alone. Chest 1995;107:401-405.
6. Sansores R, Ramirez-Vanegas A, Reddy C, Mejia-Alfaro R. Effect of the combination of two bronchodilators on breathlessness in patients with chronic obstructive pulmonary disease: a crossover clinical trial. Arch Med Res 2003;34:292-297.
7. Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999;159:156-160.
8. Donohue JF. Minimal clinically important differences in COPD lung function. Journal of COPD 2005;2:111-124.
9. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999;115:635-641.
10. Tang OT, Flatley M. A comparison of effects of inhaling a combined preparation of fenoterol with ipratropium bromide (Duovent) with those of fenoterol and salbutamol. Postgrad Med J 1984;60:24-27.
11. Huhti E, Poukkula A. Comparison of fenoterol, ipratropium bromide, and their combination in patients with asthma or chronic airflow obstruction. Respiration 1986;50:298-301.
12. Imhof E, Elsasser S, Karrer W, Grossenbacher M, Emmons R, Perruchoud AP. Comparison of bronchodilator effects of fenoterol/ipratropium bromide and salbutamol in patients with chronic obstructive lung disease. Respiration 1993;60:84-88.
13. Grassi V, Bruni B, Peccini F, Tantucci C, Todisco T. Acute on chronic comparative effects of a combination of fenoterol-ipratropium bromide and terbutaline in patients with chronic obstructive lung disease. Respiration 1986;50:226-231.
14. Tobin MJ, Hughes JA, Hutchison DC. Effects of ipratropium bromide and fenoterol aerosols on exercise tolerance. Eur J Respir Dis 1984;65:441-446.
15. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115:966-971.
16. Serra C, Giacopelli A, Luciani G. Acute controlled study of the dose-response relationship of fenoterol, ipratropium bromide and their combination. Respiration 1986;50:144-147.
17. Easton PA, Jadue C, Dhingra S, Anthonisen NR. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N Engl J Med 1986;315:735-739.
18. COMBIVENT Inhalation Aerosol Study group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: An 85-day multicenter trial. Chest 1994;105:1411-1419.
19. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997;112:1514-1521.
20. Moayyedi P, Congleton J, Page RL, Pearson SB, Muers MF. Comparison of nebulised salbutamol and ipratropium bromide with salbutamol alone in the treatment of chronic obstructive pulmonary disease. Thorax 1995;50:834-837.
21. Tashkin DP, Bleecker E, Braun S, Campbell S, DeGraff AC Jr, Hudgel DW, Boyars MC, Sahn S. Results of a multicenter study of nebulized inhalant bronchodilator solutions. Am J Med 1996;100:62S-69S.
22. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Respiration 1998;65:354-362.
23. Ram FS, Jardin JR, Atallah A, Castro AA, Mazzini R, Goldstein R, Lacasse Y, Cendon S. Efficacy of theophylline in people with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respir Med 2005;99:135-144.
24. Bleecker ER, Britt EJ. Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease. Am J Med 1991;91:24S-27S.
25. Filuk RB, Easton PA, Anthonisen NR. Responses to large doses of salbutamol and theophylline in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132:871-874.
26. Thomas P, Pugsley JA, Stewart JH. Theophylline and salbutamol improve pulmonary function in patients with irreversible chronic obstructive pulmonary disease. Chest 1992;101:160-165.
27. Tsukino M, Nishimura K, Ikeda A, Hajiro T, Koyama H, Izumi T. Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax 1998;53:269-273.
28. Bellia V, Foresi A, Bianco S, Grassi V, Olivieri D, Bensi G, Volonte M; BREATH Italian Study Group. Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial). Respir Med 2002;96:881-889.
29. Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T. The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995;107:718-723.
30. Karpel JP, Kotch A, Zinny M, Pesin J, Alleyne W. A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD. Chest 1994;105:1089-1094.
31. Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 2004;200:689-695.
32. Chapman KR, Arvidsson P, Chuchalin AG, Dhillon DP, Faurschou P, Goldstein RS, Kuipers AF; International study group. The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002;9:178-185.
33. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000;15:878-885.
34. Cazzola M, Di Perna F, Centanni S, Califano C, Donner CF, D'Amato M, D'Amato G. Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease. Thorax 1999;54:1083-1086.
35. Cazzola M, Matera MG, Di Perna E, Califano C, D'Amato M, Mazzarella G. Influence of higher than conventional doses of oxitropium bromide on formoterol-induced bronchodilation in COPD. Respir Med 1999;93:909-911.
36. Sichletidis L, Kottakis J, Marcou S, Constantinidis TC, Antoniades A. Bronchodilatory responses to formoterol, ipratropium, and their combination in patients with stable COPD. Int J Clin Pract 1999;53:185-188.
37. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, Almeida J, Sichletidis L, Rapatz G, Kottakis J; FOR-INT-03 Study Group. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001;119:1347-1356.
38. Tzelepis G, Komanapolli S, Tyler D, Vega D, Fulambarker A. Comparison of nebulized glycopyrrolate and metaproterenol in chronic obstructive pulmonary disease. Eur Respir J 1996;9:100-103.
39. Cydulka RK, Emerman CL. Effects of combined treatment with glycopyrrolate and albuterol in acute exacerbation of chronic obstructive pulmonary disease. Ann Emerg Med 1995;25:470-473.
40. Cazzola M, Centanni S, Santus P, Verga M, Mondoni M, di Marco F, Matera MG. The functional impact of adding salmeterol and tiotropium in patients with stable COPD. Respir Med 2004;98:1214-1221.
41. van Noord JA, Aumann J, Janssens E, Folgering H, Mueller A, Cornelissen PJG. Tiortopium maintenance therapy in patients with COPD and the 24-h spirometric benefit of adding once or twice daily formoterol during 2-week treatment periods [abstract A95]. Presented at American Thoracic Society 99th International Conference. Seattle, May 16-21, 2003.
42. van Noord JA, Aumann J, Janssens E, Mueller A, Cornelissen PJG. Comparison of once daily tiotropium, twice daily formoterol and the free combination, once daily, in patients with COPD [abstract A320]. Presented at American Thoracic Society 99th International Conference. Seattle, May 16-21, 2003.
43. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-1670.
44. Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000;118:1576-1581.
45. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-224.
46. Shrewbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-1373.
47. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-1411.
48. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
49. Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843.
50. Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091.
51. Yildiz F, Basyigit I, Yildirim E, Boyaci H, Ilgazli A. Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD? Respirology 2004;3:352-355.
52. Dal Negro RW, Pomari C, Tognella S, Micheletto C. Salmeterol & fluticasone 50 microg/250 microg bid in combination provides a better long-term control than salmeterol 50 microg bid alone and placebo in COPD patients already treated with theophylline. Pulm Pharmacol Ther 2003;16:241-246.
53. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax 2005;60:301-304.
54. Canonica GW, Castellani P, Cazzola M, Fabbri LM, Fogliani V, Mangrella M, Moretti A, Paggiaro P, Sanguinetti CM, Vignola AM; The CAST (Control Of Asthma By Symbicort Turbuhaler) Study Group. Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing. Pulm Pharmacol Ther 2004;17:239-247.
55. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
56. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
57. Nannini L, Gates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2004; number 3: CD003794.
58. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-1909.
59. Richy F, Bousquet J, Ehrlich GE, Meunier PJ, Israel E, Morii H, Devogelaer JP, Peel N, Haim M, Bruyere O, et al. Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review. Osteoporos Int 2003;14:179-190.
60. Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Chest 2005;127:89-97.
61. Knobil K, Yancey S, Kral K, Rickard K. Salmeterol Multi-Center Asthma Research Trial (SMART): results from an interim analysis [abstract]. Chest 2003;14:335S.
62. Corrao G, Zambon A. Faini S, Bagnardi V, Leoni O, Suissa S. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol 2005;58:92-97.
63. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest 2004;125:2309-2321.
64. Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 2002;20:819-825.
65. Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med 2003;168:49-53.
66. Suissa S. Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 2004;23:391-395.
67. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004;24:206-210.
68. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-1397.
69. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:760-765.
70. Stiksa G, Nemcek K, Melin S. Effects of inhaled N-acetylcysteine in combination with terbutaline. Eur J Respir Dis 1984;65:278-282.
71. Decramer M, Rutten-van Mölken M, Dekhuijzen PR, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CO, Olivieri D, Del Donno M, De Backer W, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 2005;365:1518-1520.
72. Cazzola M, Centanni S, Boveri B. Di Marco F, Santus P, Matera MG, Allegra L. Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease. Respiration 2001;68:452-159.
73. Celik P, Sakar A, Havlucu Y, Yuksel H, Turkdogan P, Yorgancioglu A. Short-term effects of montelukast in stable patients with moderate to severe COPD. Respir Med 2005;99:444-450.
74. Robinson DS, Campbell D, Barnes PJ. Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial. Lancet 2001;357:2007-2011.
75. Baloira Villar A, Vilarino Pombo C. Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease. Arch Bronconeumol 2005;41:130-134.
76. Aaron SD, Vandemheen K, Fergusson D, Fitzgerald M, Maltais F, Bourbeau J, Goldstein R, McIvor A, Baiter M, O'donnell D, et al. The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment. Can Respir J 2004;11:581-585.
77. Kerstjens HA, Brand PL, Hughes MD, Robinson NJ, Postma DS, Sluiter HJ, Bleecker ER, Dekhuijzen PN, de Jong PM, Mengelers HJ. A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. N Engl J Med 1992;327:1413-1419.
78. Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med. 2004;3:173-181.
79. Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown C, Knobil K. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin. Ther. 2005;27:531-542.
80. Cazzola M, Santus P, Di Marco F, Boveri B, Castagna F, Carlucci P, Matera MG, Centanni S. Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPD. Respir Med 2003;97:453-457.
81. Aalbers R, Backer V, Kava TT, Omenaas ER, Sandstrom T, Jorup C, Welte T. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004;20:225-240.
82. FitzGerald JM, Boulet L-P, Follows RMA. The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 2005;27:1311-1315.
83. Douglas NJ, Davidson I, Sudlow MF, Flenley DC. Bronchodilatation and the site of airway resistance in severe chronic bronchitis. Thorax 1979;34:51-56.
84. Newnham DM, Dhillon DP, Winter JH, Jackson CM, Clark RA, Lipworth BJ. Bronchodilator reversibility to low and high doses of terbutaline and ipratropium bromide in patients with chronic obstructive pulmonary disease. Thorax 1993;48:1151-1155.
85. Cazzola M, Di Perna F, Califano C, Vinciguerra A, D'Amato M. Incremental benefit of adding oxitropium bromide to formoterol in patients with stable COPD. Pulm Pharmacol Ther 1999;12:267-271.
86. Chrischilles E, Gilden D, Kubisiak J, Rubenstein L, Shah H. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two-in-one inhaler versus separate inhalers. Am J Manag Care 2002;8:902-911.
87. Benayoun S, Ernst P, Suissa S. The impact of combined inhaled bronchodilator therapy in the treatment of COPD. Chest 2001;119:85-92.
88. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol 2003;112:29-36.
89. Barnes PJ. A single inhaler for asthma? Am J Respir Crit Care Med 2005;171:95-96.
90. Kassner F, Hodder R, Bateman ED. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease. Drugs 2004;64:1671-1682.
91. Kilfeather SA, Ponitz HH, Beck E, Schmidt P, Lee A, Bowen I, Hesse Ch. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD. Respir Med 2004;98:387-397.
92. Rammeloo RH, Luursema PB, Sips AP, Beumer HM, Wald FD, Cornelissen PJ. Therapeutic equivalence of a fenoterol/ipratropium bromide combination (Berodual) inhaled as a dry powder and by metered dose inhaler in chronic obstructive airway disease. Respiration 1992;59:322-326.
93. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653.
94. Shim CS, Williams MH Jr. Bronchodilator response to oral aminophylline and terbutaline versus aerosol albuterol in patients with chronic obstructive pulmonary disease. Am J Med 1983;75:697-701.
95. Vestbo J, Soriano JB, Anderson JA, Calverley P, Pauwels R, Jones P. Sex does not influence the response to the combination of salmeterol and fluticasone propionate in COPD. Respir Med 2004;98:1045-1050.
96. 1. The Lung Health Study. JAMA 1994;272:1497-1505.
97. 1 in patients with chronic obstructive pulmonary disease: a meta-analysis. Ann Intern Med 2003;138:969-973.
98. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in CLPD: the UPLIFT trial. COPD 2004;1:303-312.
99. Welte T. Fixed combination of a long-acting beta(2)-agonist and an inhaled steroid: a therapeutic option for COPD? Med Klin 2003;98:552-561.